9 completed, 8 unknown, 7 terminated, 7 withdrawn. 41 Phase 1, 23 Phase 2.
Follow Nab paclitaxel: new trials by email Literature Review of Nab paclitaxel trials Research Report on Nab paclitaxel
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of GFH276 Combined With Cetuximab or Chemotherapy in Participants With Solid Tumors and Pancreatic Ductal Adenocarcinoma (PDAC) Harboring RAS Mutation GFH276, Cetuximab, Nab paclitaxel - Advanced Solid Tumors Cancer, Pancreatic Ductal Adenocarcinoma | Phase 1 / Phase 2 | Recruiting | Genfleet Therapeutics (Shanghai) Inc. | 222 | 2026-09-01 | 2026-10-05 |
| ONT01 and Gemcitabine/Nab-paclitaxel as Second Line Therapy for Metastatic Pancreatic Ductal Adenocarcinoma ONT01, Gemcitabine, Nab paclitaxel - Metastatic Pancreatic Ductal Adenocarcinoma | Phase 1 / Phase 2 | Recruiting | Washington University School of Medicine | 61 | 2026-03-25 | 2026-05-19 |
| Basal-like PDAC Treated With Gemcitabine, Erlotinib, and Nab-paclitaxel Gemcitabine, Nab paclitaxel, Erlotinib - Pancreatic Adenocarcinoma, Metastatic Pancreatic Cancer | Phase 1 / Phase 2 | Recruiting | UNC Lineberger Comprehensive Cancer Center | 104 | 2025-02-06 | 2026-04-23 |
| The Seven Trial: Exploiting the Unfolded Protein Response Botensilimab, Balstilimab, Chloroquine Phosphate - Pancreatic Cancer Metastatic, Pancreatic Adenocarcinoma Metastatic | Phase 1 | Terminated | HonorHealth Research Institute | 6 | 2025-01-09 | 2026-06-23 |
| A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors LY4066434., Cetuximab, Nab paclitaxel - Pancreatic Ductal Adenocarcinoma, Non-small Cell Lung Cancer | Phase 1 | Active not recruiting | Eli Lilly and Company | 750 | 2024-10-21 | 2026-07-20 |
| A Study of LY4050784 in Participants With Advanced or Metastatic Solid Tumors LY4050784, Pembrolizumab, Cisplatin - Metastatic Solid Tumor, Advanced Solid Tumor | Phase 1 | Recruiting | Eli Lilly and Company | 340 | 2024-09-19 | 2026-09-08 |
| Newly Emerging Immunotherapy for Pancreatic Cancer Treatment JS001, JS004, JS007 - Pancreatic Cancer | Phase 1 / Phase 2 | Not yet recruiting | Fudan University | 117 | 2024-04-30 | 2024-04-17 |
| Surufatinib Combined With KN046 and AG Regimen Chemotherapy as First-Line Treatment for Unresectable Advanced Pancreatic Cancer surufatinib, KN046, gemcitabine - Unresectable Locally Advanced or Metastatic Pancreatic Cancer | Phase 1 / Phase 2 | Unknown | Shanghai Zhongshan Hospital | 41 | 2023-11-01 | 2024-06-14 |
| Proglumide With Gemcitabine and Nab-Paclitaxel in PatientsWith Metastatic Pancreatic Ductal Adenocarcinoma Gemcitabine, Nab paclitaxel, Proglumide Dose level 1 - Metastatic Pancreatic Cancer | Phase 1 | Withdrawn | Georgetown University | 2023-10-01 | 2023-10-25 | |
| A Study of QLS31905 Combination Chemotherapy as First-Line Treatment in Patients With Advanced Solid Tumors QLS31905, Nab paclitaxel, Gemcitabine - Solid Tumor | Phase 1 / Phase 2 | Unknown | Qilu Pharmaceutical Co., Ltd. | 115 | 2023-10-01 | 2023-09-18 |
| IFNα Expressing Mesenchymal Stromal Cells for Locally Advanced/Metastatic Solid Tumors MSC-IFNα, Nab paclitaxel, Cyclophosphamide - Locally Advanced or Metastatic Solid Tumors | Phase 1 / Phase 2 | Recruiting | Chinese PLA General Hospital | 40 | 2023-02-23 | 2023-04-28 |
| A Trial of Cobicistat and Gemcitabine and Nab-Paclitaxel in Patients with Advanced Stage or Metastatic Pancreatic Ductal Adenocarcinoma Cobicistat Oral Tablet, Gemcitabin, Nab paclitaxel - CYP3A Inhibitor, Advanced Stage or Metastatic Pancreatic Ductal Adenocarcinoma | Phase 1 | Terminated | German Cancer Research Center | 6 | 2022-12-07 | 2025-03-25 |
| A Phase 1b Study of Gemcitabine and Nab-paclitaxel in Combination With IM156 in Patients With Advanced Pancreatic Cancer. Gemcitabine, Nab paclitaxel, IM156 - Pancreas Cancer | Phase 1 | Active not recruiting | M.D. Anderson Cancer Center | 19 | 2022-10-21 | 2026-10-07 |
| Study of Sotorasib Combined With Chemotherapy for Second Line Treatment of Pancreas Cancer Sotorasib, Liposomal Irinotecan (nal-IRI), 5 Fluorouracil (5FU) - Pancreatic Cancer, Unresectable Pancreatic Cancer | Phase 1 / Phase 2 | Withdrawn | Devalingam Mahalingam | 2022-09-13 | 2023-05-11 | |
| Afuresertib +Sintilimab+Chemotherapy in Patients With Selected Solid Tumors That Resistance to Prior Anti-PD-1/PD-L1 Afuresertib, Nab paclitaxel, Docetaxel - Solid Tumor, NSCLC | Phase 1 / Phase 2 | Completed | Laekna Limited | 22 | 2022-07-01 | 2025-11-17 |
| Combination of Serabelisib and Insulin Suppressing Diet With or Without Nab-paclitaxel in Subjects With Advanced Solid Tumors With PIK3CA Mutations Serabelisib, Insulin Suppressing Diet, Nab paclitaxel - Advanced Solid Tumor, PIK3CA Mutation | Phase 1 | Terminated | Faeth Therapeutics | 34 | 2022-04-22 | 2026-04-30 |
| Nab-paclitaxel Compared With Docetaxel in the Neoadjuvant Chemotherapy Breast Cancer Nab paclitaxel, Docetaxel - Breast Cancer, Chemotherapy Effect | Phase 1 | Unknown | Xuli Meng | 30 | 2022-04-20 | 2022-02-23 |
| An Open-label, Phase I/II Study of PLENA Regimen in Patients With Unresectable Pancreatic Cancer or BTC Durvalumab, Lenvatinib, Nab paclitaxel - Pancreatic Cancer, Biliary Tract Cancer | Phase 1 / Phase 2 | Unknown | Chinese PLA General Hospital | 65 | 2022-04-12 | 2022-04-14 |
| POL6326 (Balixafortide) Plus Nab-paclitaxel or Eribulin in Patients With HER2-negative Advanced Breast Cancer POL6326, Eribulin, Nab paclitaxel - Advanced Breast Cancer | Phase 1 / Phase 2 | Withdrawn | MedSIR | 2022-03-16 | 2023-03-20 | |
| Study to Evaluate the Safety and Efficacy of Treatment With NLM-001 and Standard Chemotherapy Plus Zalifrelimab in Patients With Advanced Pancreatic Cancer Gemcitabine, Nab paclitaxel, NLM-001 - Pancreatic Ductal Adenocarcinoma | Phase 1 / Phase 2 | Active not recruiting | Nelum Corp | 28 | 2021-09-01 | 2024-12-30 |
Showing 20 of 41. Sign in to see all of them.
Pancreatic Neoplasms (16) · Carcinoma, Non-Small-Cell Lung (6) · Breast Neoplasms (5) · Neoplasms (4) · Adenocarcinoma (3) · Colorectal Neoplasms (3) · Lung Neoplasms (3) · Neoplasm Metastasis (3) · Carcinoma, Ovarian Epithelial (2) · Endometrial Neoplasms (2) · Esophageal Neoplasms (2) · Ovarian Neoplasms (2) · Peritoneal Neoplasms (2) · Squamous Cell Carcinoma of Head and Neck (2) · Biliary Tract Neoplasms (1)
Chinese PLA General Hospital (2) · Eli Lilly and Company (2) · ImmunityBio, Inc. (2) · University of Chicago (2) · Aravive, Inc. (1) · Ascentage Pharma Group Inc. (1) · BeiGene (1) · Benaroya Research Institute (1) · City of Hope Medical Center (1) · Devalingam Mahalingam (1) · Dragonfly Therapeutics (1) · Faeth Therapeutics (1) · Fudan University (1) · Genfleet Therapeutics (Shanghai) Inc. (1) · Genmab (1)
United States (24) · China (10) · Germany (6) · France (5) · Spain (5) · South Korea (4) · Australia (3) · Denmark (3) · Taiwan (3) · Belgium (2) · Italy (2) · Japan (2) · Georgia (1) · Israel (1) · Moldova (1)
Amy J Chien, MD (1) · Ashwin Somasundaram, MD (1) · Benjamin WE, MD (1) · Deborah L. Toppmeyer, MD (1) · Devalingam Mahalingam, MD (1) · Intidhar Labidi-Galy, MD, PhD (1) · Jonas de Souza (1) · Lin Shen, Director (1) · Mihaela Cristea, MD (1) · Mohammed N Al Hallak, M.D. (1) · Nicolas Hohmann, PD Dr. med. (1) · Patrick Grierson, M.D., Ph.D. (1)
PMID 30623229, PMID 31831564, PMID 35688554, PMID 35945244, PMID 36604127, PMID 37857528, PMID 37920921, PMID 38135184, PMID 38191175, PMID 40272619, PMID 40347227, PMID 40975066, PMID 41271741
2018 (2), 2019 (1), 2023 (1), P30CA016056 (1), P30CA072720 (1), P50CA272213 (1)